Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

• Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
  • Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract
• Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13)
  • Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract
  • Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.
• Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06)
  • VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.
• Selective review of trials of oral SERDs in the adjuvant setting (11:27)
  • A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054

CME information and select publications